Long-Term Drug Therapy and Drug Holidays for Osteoporotic Fracture Prevention
Santaguida, J. Stroke, venous thromboembolic disease pulmonary embolism, deep venous thrombosis , hot flashes, mild cognitive impairment, dementia, mortality.
Previous fractures at multiple sites increase the risk for subsequent fractures: As osteoporosis is a public health problem associated with morbidity and socio-economic burden worldwide. Camacho, S.
Osteoporosis - Living with - NHS
Berliner, D. Marsh, E. Wilt, L.
Abstract Summary Osteoporosis causes an elevated fracture risk. Clines, J. Final health outcomes: Grading the Strength of Evidence SOE for Major Comparisons and Outcomes Two investigators will independently assess five required domains and other possible factors to grade the strength of evidence within each treatment comparison for included studies. Further considerations The committee believes that expanding the diagnostic criteria for osteoporosis will assist in properly identifying a greater number of people who are, in fact, at an elevated risk for fracture, thus increasing awareness and encouraging strategies to lower risk, which may or may not include prescription therapy in all cases but would be recommended by current guidelines for most [ 3 ].
Osteoporosis International. Wang, J. Quandt, S. We will search Ovid Medline, Ovid Embase, and the Cochrane Central Register of Controlled Trials CENTRAL to identify randomized controlled trials, nonrandomized controlled trials, and observational studies published and indexed in these bibliographic databases since , which is the first year an RCT on osteoporosis treatment was published for any of the interventions included in this review.
Osteoporosis: A Silent Killer
Osteonecrosis of the jaw, atypical femoral fracture, atrial fibrillation, heart attacks, musculoskeletal pain, upper GI intolerance, esophageal cancer Denosumab: Types of potential bias we will evaluate for each eligible study will include: Because risks of hip, vertebral and other fractures rise steeply with age, and because the population is aging, the absolute number of these fractures is projected to increase substantially in coming decades.
The failure to detect clinical osteoporosis when it is present likely contributes to the current lack of awareness of the consequences of this disease by both clinicians and patients, impacts the reimbursement strategies of payers, influences policy makers in the public health sector by underestimating the number of those at elevated fracture risk, and affects the design of clinical trials of new agents to reduce fracture risk by both pharmaceutical companies and the FDA.
El-Hajj Fuleihan, D. An overall rating of high strength of evidence would be assigned when included studies were RCTs with a low risk of bias, and the results were consistent, direct, and precise.
Zoledronic acid and clinical fractures and mortality after hip fracture. While many other fracture types increase the risk of future fractures [ 10 ], the committee did not feel that all fracture types, beyond those listed here, would necessarily constitute a basis for an osteoporosis diagnosis.
So we must develop clinical tools to assess clinically the patients who are at greater risk of developing osteoporosis [ 10 ]. Studies considered ineligible by two of these investigators will be excluded from the review, while those considered potentially eligible by at least one of these investigators will be forwarded for full text screening.
AHRQ Ed. Buckley, E. References 1. Studies determined to be high risk of bias will have only limited data extracted, most of which will have been obtained using Distiller during full text eligibility screening: Updates on the clinical assessment and treatment of osteoporosis in CKD anno will be presented through state of the art lectures given by key opinion leaders and the interactive voting system encouraging discussion.
Number of users per countries N.